JP2017537896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537896A5 JP2017537896A5 JP2017525022A JP2017525022A JP2017537896A5 JP 2017537896 A5 JP2017537896 A5 JP 2017537896A5 JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017537896 A5 JP2017537896 A5 JP 2017537896A5
- Authority
- JP
- Japan
- Prior art keywords
- hvr
- amino acid
- seq
- acid sequence
- region polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 83
- 229920001184 polypeptide Polymers 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 230000035772 mutation Effects 0.000 claims 17
- 235000001014 amino acid Nutrition 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 3
- 102000058223 human VEGFA Human genes 0.000 claims 3
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 2
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 208000014245 Ocular vascular disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192517.2 | 2014-11-10 | ||
| EP14192517 | 2014-11-10 | ||
| PCT/EP2015/075879 WO2016075037A1 (en) | 2014-11-10 | 2015-11-06 | Bispecific antibodies and methods of use in ophthalmology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537896A JP2017537896A (ja) | 2017-12-21 |
| JP2017537896A5 true JP2017537896A5 (cg-RX-API-DMAC7.html) | 2018-12-06 |
Family
ID=51868112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525022A Pending JP2017537896A (ja) | 2014-11-10 | 2015-11-06 | 二重特異性抗体及び眼科に使用する方法 |
Country Status (15)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| SG11201703458UA (en) * | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| US10836819B2 (en) | 2016-08-23 | 2020-11-17 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| MY199149A (en) * | 2018-12-21 | 2023-10-18 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021198034A1 (en) * | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
| EP4349861A4 (en) * | 2021-06-04 | 2025-07-23 | Innovent Biologics Suzhou Co Ltd | BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND ITS USE |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025211874A1 (ko) * | 2024-04-04 | 2025-10-09 | 주식회사 크로스포인트테라퓨틱스 | 인간 항체 fc 변이체 포함 이중항체 및 그 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| AU2003208946A1 (en) | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| CA2509136C (en) | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| EP1587830B1 (en) | 2003-01-28 | 2009-07-08 | Academisch Ziekenhuis Leiden | Peptide inhibitors of toxins derived from ll-37 |
| US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| EP3351269B1 (en) | 2005-06-14 | 2020-01-29 | Amgen Inc. | Self-buffering protein formulations |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| CA2727171A1 (en) | 2008-06-06 | 2009-12-10 | Xoma Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| EP2391652A4 (en) | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
| EP2488201A4 (en) | 2009-10-15 | 2013-12-25 | Abbvie Inc | IL-1 BINDING PROTEINS |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| AR080793A1 (es) * | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| CN102883748A (zh) * | 2010-05-07 | 2013-01-16 | 爱克索马技术有限公司 | 治疗IL-1β相关状况的方法 |
| MX2013001267A (es) | 2010-08-13 | 2013-04-10 | Genentech Inc | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. |
| RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| CA2821976A1 (en) | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| CA2830254C (en) | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
| JP6069312B2 (ja) | 2011-06-29 | 2017-02-01 | アムジェン インコーポレイテッド | 腎細胞癌の治療における生存の予測バイオマーカー |
| EP2867360B1 (en) * | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| KR20150060686A (ko) | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물 |
| CN104661678A (zh) | 2012-09-28 | 2015-05-27 | 勃林格殷格翰国际有限公司 | 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合 |
| BR112015010566A2 (pt) | 2012-11-08 | 2017-07-11 | Clearside Biomedical Inc | métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos |
| EP2917237A1 (en) * | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
| UA118029C2 (uk) * | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| PE20160753A1 (es) | 2013-12-20 | 2016-08-01 | Hoffmann La Roche | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| SG11201703458UA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| US20190004048A1 (en) | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
| US11198726B2 (en) | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
-
2015
- 2015-11-06 KR KR1020177011694A patent/KR20170080584A/ko not_active Withdrawn
- 2015-11-06 MX MX2017005977A patent/MX2017005977A/es unknown
- 2015-11-06 RU RU2017120360A patent/RU2017120360A/ru not_active Application Discontinuation
- 2015-11-06 CA CA2963175A patent/CA2963175A1/en not_active Abandoned
- 2015-11-06 AU AU2015345323A patent/AU2015345323A1/en not_active Abandoned
- 2015-11-06 WO PCT/EP2015/075879 patent/WO2016075037A1/en not_active Ceased
- 2015-11-06 CN CN201580060833.XA patent/CN107074941A/zh active Pending
- 2015-11-06 EP EP15790946.6A patent/EP3218399A1/en not_active Withdrawn
- 2015-11-06 JP JP2017525022A patent/JP2017537896A/ja active Pending
- 2015-11-06 BR BR112017009764A patent/BR112017009764A2/pt not_active Application Discontinuation
- 2015-11-06 SG SG11201703428SA patent/SG11201703428SA/en unknown
- 2015-11-09 AR ARP150103645A patent/AR102592A1/es unknown
- 2015-11-09 TW TW104136909A patent/TW201632551A/zh unknown
-
2017
- 2017-03-13 IL IL251128A patent/IL251128A0/en unknown
- 2017-05-09 US US15/590,176 patent/US10730938B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537896A5 (cg-RX-API-DMAC7.html) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| JP2017534646A5 (cg-RX-API-DMAC7.html) | ||
| JP2017504566A5 (cg-RX-API-DMAC7.html) | ||
| JP2020062036A5 (cg-RX-API-DMAC7.html) | ||
| JP2017534645A5 (cg-RX-API-DMAC7.html) | ||
| HRP20211357T1 (hr) | Bispecifična protutijela specifična za pd-1 i tim3 | |
| JP2017534644A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200384T1 (hr) | Humanizirana anti-tau(ps422) protutijela i načini uporabe | |
| RU2019134338A (ru) | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 | |
| JP2018537966A5 (cg-RX-API-DMAC7.html) | ||
| HRP20241775T1 (hr) | Bispecifična protutijela koja se specifično vežu na pd1 i lag3 | |
| JP2019501883A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220304T1 (hr) | Anti-transferinska receptorska protutijela s prilagođenim afinitetom | |
| HRP20211528T1 (hr) | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije | |
| JP2018522541A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533441A5 (cg-RX-API-DMAC7.html) | ||
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| HRP20191766T1 (hr) | Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene | |
| RU2016133347A (ru) | Варианты fc-области с улучшенной способностью связываться с белком а | |
| HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
| JP2019502712A5 (cg-RX-API-DMAC7.html) | ||
| RU2016124325A (ru) | Антитела к альфа-синуклеину и способы применения | |
| RU2016133345A (ru) | Варианты fc-области с модифицированными способностями связываться с fcrn | |
| RU2016133346A (ru) | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |